These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 73588)

  • 1. Quantum chemical studies of N-substituent variation in the oxymorphone series of opiate narcotics.
    Loew GH; Berkowitz DS
    J Med Chem; 1978 Jan; 21(1):101-6. PubMed ID: 73588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands.
    Fang X; Larson DL; Portoghese PS
    J Med Chem; 1997 Sep; 40(19):3064-70. PubMed ID: 9301669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxymorphone-naltrexonazine, a mixed opiate agonist-antagonist.
    Galetta S; Hahn EF; Nishimura S; Pasternak GW
    Life Sci; 1987 Aug; 41(6):783-7. PubMed ID: 2441221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity studies of narcotic agonists and antagonists from quantum chemical calculations.
    Loew GH; Berkowitz DS; Burt SK
    NIDA Res Monogr; 1978; (22):278-316. PubMed ID: 213725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irreversible opiate agonists and antagonists. II. Evidence against a bivalent mechanism of action for opiate azines and diacylhydrazones.
    Hahn EF; Nishimura S; Goodman RR; Pasternak GW
    J Pharmacol Exp Ther; 1985 Dec; 235(3):839-45. PubMed ID: 2416909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irreversible opiate agonists and antagonists. III. Phenylhydrazone derivatives of naloxone and oxymorphone.
    Hahn EF; Itzhak Y; Nishimura S; Johnson N; Pasternak GW
    J Pharmacol Exp Ther; 1985 Dec; 235(3):846-50. PubMed ID: 2416910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting opiate agonists and antagonists: 14-hydroxydihydromorphinone hydrazones.
    Pasternak GW; Hahn EF
    J Med Chem; 1980 Jun; 23(6):674-6. PubMed ID: 6156240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 10-Ketonaltrexone and 10-ketooxymorphone.
    Archer S; Seyed-Mozaffari A; Ward S; Kosterlitz HW; Paterson SJ; McKnight AT; Corbett AD
    J Med Chem; 1985 Jul; 28(7):974-6. PubMed ID: 2409281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agonist-antagonist properties of fluorescent opioid probes in the guinea-pig myenteric plexus-longitudinal muscle preparation.
    Koman A; Einarsson M; Terenius L
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Dec; 331(4):355-8. PubMed ID: 2419770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological studies with an alkylating narcotic agonist, chloroxymorphamine, and antagonist, chlornaltrexamine.
    Caruso TP; Larson DL; Portoghese PS; Takemori AE
    J Pharmacol Exp Ther; 1980 Jun; 213(3):539-44. PubMed ID: 6162947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
    Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
    J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphine analgesia after intrathecal administration of a narcotic agonist, chloroxymorphamine and antagonist, chlornaltrexamine.
    Larson AA; Armstrong MJ
    Eur J Pharmacol; 1980 Nov; 68(1):25-31. PubMed ID: 6161013
    [No Abstract]   [Full Text] [Related]  

  • 13. Diastereomeric 6-desoxy-6-spiro-alpha-methylene-gamma-butyrolactone derivatives of naltrexone and oxymorphone. Selective irreversible inhibition of naltrexone binding in an opioid receptor preparation by a conformationally restricted michael acceptor ligand.
    Koolpe GA; Nelson WL; Gioannini TL; Angel L; Simon EJ
    J Med Chem; 1984 Dec; 27(12):1718-23. PubMed ID: 6209395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity studies of morphine fragments. I. 4-alkyl-4-(m-hydroxy-phenyl)-piperidines.
    Loew GH; Lawson JA; Uyeno ET; Toll L; Frenking G; Polgar W; Ma LY; Camerman N; Camerman A
    Mol Pharmacol; 1988 Sep; 34(3):363-76. PubMed ID: 2843751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intramolecular hydrogen bonding and conformational studies of bridged thebaine and oripavine opiate narcotic agonists and antagonists.
    Loew GH; Berkowitz DS
    J Med Chem; 1979 Jun; 22(6):603-7. PubMed ID: 458815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantum chemical studies of morphine-like opiate narcotics. Effect of N-substituent variations.
    Loew GH; Berkowitz DS
    J Med Chem; 1975 Jul; 18(7):656-62. PubMed ID: 1151985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chloroxymorphamine, and opioid receptor site-directed alkylating agent having narcotic agonist activity.
    Caruso TP; Takemori AE; Larson DL; Portoghese PS
    Science; 1979 Apr; 204(4390):316-8. PubMed ID: 86208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid agonists and antagonists. 6-Desoxy-6-substituted lactone, epoxide, and glycidate ester derivatives of naltrexone and oxymorphone.
    Koolpe GA; Nelson WL; Gioannini TL; Angel L; Appelmans N; Simon EJ
    J Med Chem; 1985 Jul; 28(7):949-57. PubMed ID: 2409280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irreversible opiate agonists and antagonists: the 14-hydroxydihydromorphinone azines.
    Hahn EF; Carroll-Buatti M; Pasternak GW
    J Neurosci; 1982 May; 2(5):572-6. PubMed ID: 6176696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological investigations of N-substituent variation in morphine and oxymorphone: opioid receptor binding, signaling and antinociceptive activity.
    Ben Haddou T; Béni S; Hosztafi S; Malfacini D; Calo G; Schmidhammer H; Spetea M
    PLoS One; 2014; 9(6):e99231. PubMed ID: 24919067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.